Milder chemo shows promise for HER2+ breast cancer patients
NCT ID NCT07421141
First seen Feb 21, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This study tests a less intense chemotherapy combination (paclitaxel, trastuzumab, and pertuzumab) for people with early-stage HER2-positive breast cancer. The goal is to see if this gentler approach works as well as the standard stronger regimen, with fewer side effects. 186 participants are involved, and the main measure is whether the cancer disappears completely by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
P.A. Hertsen Moscow Oncology Research Institute
Moscow, 125284, Russia
Conditions
Explore the condition pages connected to this study.